Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Mutch

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Gynecologic Oncology|September 30, 2022
High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancerElizabeth Buckley, Mary M Mullen, Rehan A Nizamuddin, et al.
Cancer|January 30, 2024
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancerDavid Mutch, Athina Voulgari, Xian Marissa Chen, et al.
Gynecologic Oncology|September 6, 2015
Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trialAshley S Felix, D Scott McMeekin, David Mutch, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2024
FIGO 2023 staging for endometrial cancer, when, if it is not now?Xavier Matias-Guiu, Sigurd Lax, Maria Rosaria Raspollini, et al.
British Journal of Cancer|November 8, 2017
Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancerStephanie Markovina, Songyan Wang, Lauren E Henke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
<i>TP53</i> Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyKristina W Thiel, Eric J Devor, Virginia L Filiaci, et al.
International Journal of Radiation Oncology, Biology, Physics|September 2, 2021
Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian CancerLauren E Henke, Jennifer A Stanley, Clifford Robinson, et al.
The New England Journal of Medicine|June 13, 2019
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial CancerDaniela Matei, Virginia Filiaci, Marcus E Randall, et al.
Gynecologic Oncology|January 24, 2025
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258Aine Clements, Danielle Enserro, Kyle C Strickland, et al.
Gynecologic Oncology|October 4, 2017
Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group studyEric J Devor, Jeffrey Miecznikowski, Brandon M Schickling, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Gynecologic Oncology|September 30, 2022
High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancerElizabeth Buckley, Mary M Mullen, Rehan A Nizamuddin, et al.
Cancer|January 30, 2024
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancerDavid Mutch, Athina Voulgari, Xian Marissa Chen, et al.
Gynecologic Oncology|September 6, 2015
Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trialAshley S Felix, D Scott McMeekin, David Mutch, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2024
FIGO 2023 staging for endometrial cancer, when, if it is not now?Xavier Matias-Guiu, Sigurd Lax, Maria Rosaria Raspollini, et al.
British Journal of Cancer|November 8, 2017
Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancerStephanie Markovina, Songyan Wang, Lauren E Henke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
<i>TP53</i> Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyKristina W Thiel, Eric J Devor, Virginia L Filiaci, et al.
International Journal of Radiation Oncology, Biology, Physics|September 2, 2021
Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian CancerLauren E Henke, Jennifer A Stanley, Clifford Robinson, et al.
The New England Journal of Medicine|June 13, 2019
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial CancerDaniela Matei, Virginia Filiaci, Marcus E Randall, et al.
Gynecologic Oncology|January 24, 2025
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258Aine Clements, Danielle Enserro, Kyle C Strickland, et al.
Gynecologic Oncology|October 4, 2017
Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group studyEric J Devor, Jeffrey Miecznikowski, Brandon M Schickling, et al.
Pageof 9